Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Former Justice Department paralegal Sean Dunn, who went viral this summer for chucking a Subway sandwich at a Customs and ...

Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...

Sunday 9 November 2025 marks the fifth anniversary of a defining moment in stock market history. Pfizer/BioNTech’s ...

Pfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Stock futures are sharply higher amid hopes that the U.S. government shutdown could end soon, while investors prepare for a ...

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same time frame last year. That came after vaccine sales rose the first two ...

Donald Trump engages in ad hoc agreements with individual companies and governments to expand his power. Some observers have described these actions as a new “economic nationalism”—but that term fails ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral ...